FDA approves first interchangeable biosimilar to Perjeta to treat certain types of breast cancer
Action FDA approved Poherdy (pertuzumab-dpzb) injection as an interchangeable biosimilar biological product to Perjeta (pertuzumab). Poherdy (pertuzumab-dpzb) is the first biosimilar approved for Perjeta (pertuzumab). Poherdy is approved for the following …